Men's Health

Insurance coverage has expanded for an epigenetic test for prostate cancer and percutaneous tibial nerve stimulation (PTNS) for the treatment of overactive bladder (OAB).

The top 10 Urology Times articles of 2013 encompass topics including prostate biopsy, the urology work force, and PSA screening.

The latest products and services from Lambert Academic Publishing, the AUA, United Guardian, and SpryPublishing.

Researchers say they have linked high testosterone levels in men to a poor immune response to an influenza vaccine.

With a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.

Out-of-pocket costs for couples being treated for infertility range from a low of $912 for medication only to $19,234 for in vitro fertilization, according to researchers who say their data will help couples plan for the expenses they may incur.

Risk classification changed in more than half of prostate cancers following assessment of cell cycle progression in tumors, according to a study reported at the Society of Urologic Oncology meeting in Bethesda, MD.

In this article, we briefly review the evaluation of patients with PPI and discuss the benefits and drawbacks of conservative, pharmacologic, injection, and surgical treatments.

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop there, according to recent study.

The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).

The AUA recently joined with the American Association of Clinical Urologists and the Large Urology Group Practice Association in applauding the Physician’s Caucus of the United States Senate for their “commitment to preserving patient access to independent, integrated medical services.”

Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”

British scientists have discovered that the presence of a specific protein can distinguish between indolent and aggressive prostate cancer.

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.

Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.

The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.

Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score than men who ate a typical Western diet, UCLA researchers reported.

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has metastasized to the bones, according to a recent analysis.

Older men with midrange testosterone levels tend to live longer compared with men who have low or high levels, Australian researchers say.

GenomeDx Biosciences has entered into contractual agreements for diagnostic laboratory testing as a participating provider that will expand insurance coverage for the company’s Decipher test for prostate cancer.

Contrary to popular belief and scientific predictions, a man’s patency after vasectomy reversal is possible almost 40 years after the original vasectomy, according to a study of more than 1,200 reversals that the authors say is the largest such study ever published.

Men with prostate cancer treated with androgen deprivation therapy had significant improvement in strength and exercise capacity following a 10-week program of physical activity, education, and support, according to a study reported at the AUA annual meeting in San Diego.

Astellas Pharma US, Inc. and Medivation, Inc. have initiated a phase IV trial to evaluate the benefit of continued treatment with enzalutamide (Xtandi) beyond disease progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Men with advanced prostate cancer had similar survival with intermittent or continuous androgen deprivation therapy, pooled data from two randomized trials showed.

Data are lacking to recommend for or against the use of vitamins, minerals, and multivitamin supplements for the prevention of cancer and cardiovascular disease, according to a new U.S. Preventive Services Task Force draft recommendation statement.